KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Asset Writedowns and Impairment (2016 - 2025)

Historic Asset Writedowns and Impairment for Neogenomics (NEO) over the last 13 years, with Q4 2025 value amounting to $673000.0.

  • Neogenomics' Asset Writedowns and Impairment rose 30299.4% to $673000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $27.8 million, marking a year-over-year increase of 881025.64%. This contributed to the annual value of $27.8 million for FY2025, which is 546000.0% up from last year.
  • Latest data reveals that Neogenomics reported Asset Writedowns and Impairment of $673000.0 as of Q4 2025, which was up 30299.4% from $7.1 million recorded in Q3 2025.
  • Neogenomics' Asset Writedowns and Impairment's 5-year high stood at $20.0 million during Q2 2025, with a 5-year trough of $43000.0 in Q3 2023.
  • Over the past 4 years, Neogenomics' median Asset Writedowns and Impairment value was $718000.0 (recorded in 2022), while the average stood at $3.4 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first plummeted by 8429.04% in 2024, then skyrocketed by 30299.4% in 2025.
  • Neogenomics' Asset Writedowns and Impairment (Quarter) stood at $718000.0 in 2022, then tumbled by 94.01% to $43000.0 in 2023, then skyrocketed by 288.37% to $167000.0 in 2024, then surged by 302.99% to $673000.0 in 2025.
  • Its last three reported values are $673000.0 in Q4 2025, $7.1 million for Q3 2025, and $20.0 million during Q2 2025.